Clinical Investigation Of Gefitinib On The Treatment In Old Age Advanced NSCLC

Objective: To evaluate the response and the side-effects of Gefitinib on the advanced stage treatment to the older patients of non-small cell lung cancer, and compare and analyze the response and side-effect of Gefitinib on the First and Second Line appliance.Methods: The investigation collected the data of 16 non-small cell lung cancer old patients(Age≥60 years) who took Gefitinib on the first line and 61 non-small cell lung cancer old patients who took Gefitinib on the second line,all of them belong to the Second Clinical Hospital of Dalian Medical University from April 2003 to March 2008,then to evaluate the response and side-effects of Gefitinib, and analyze and compare the response and side-effect of Gefitinib on the First and Second Line appliance.Results: Among 16 patients who take Gefitinib on the First Line, CR, PR, SD,PD were 0%(0/16),37.5%(6/16),50%(8/16),12.5%(2/16). CR+PR 37.5% ,CR+PR+SD 87.5%(14/16).Adverse events: rash 37.5%(6/16),dry skin 18.75%(3/16), itching of skin: 12.5%(2/16),diarrhea 31.25(5/16) ,and hepatic dysfunction (GPT increase): 12.5%(2/16). Among 61 patients who take gefitinib on the First Line, CR, PR, CR, PR, SD,PD were 3.3%(2/61),26.2%(16/61),41%(25/61),29.5%(18/61),CR+PR29.5%(18/61), CR+PR+SD 70.5%(43/61).Adverse events:tetter49.2%(30/61),diarrhea 23%(14/61) ,and hepatic dysfunction (GPT increase): 9.8%(6/61),other side-effects:10%. We investigated 77 non-small cell lung cancer old patient ,and find that the lysis time of clinical symptoms of them is between 4 and 12 days.We give 70 patients who took Gefitinib the Ps mark 1~2; 50 patients' PS mark declines by 1~2;10 patients whose PS mark is 2 remain as before.We give 5 patienes who took Gefitinib the PS mark 3 ;The PS mark of 4 patients whose previous mark was 4 delines by 1;2 patients whose PS mark was 4 remain as before after they took Gefitinib .According to the comparison of statistics,we find that the PS mark of 77 patienes who took Gefitinib improves. There is no difference of the Ps mark in the patients who took Gefitinib between the first line and the second line .Conclusion: Conclusion: Gefitinib is active on the treatment in old age advanced stage non-small cell lung cancer.The rate of CR+PR is higher,while the side-effect of Gefitinib is lighter.Gefitinib can improve the survival quality and be used by the pations whose PS mark is 2 or over that.It is well tolerated with adverse events. There is no difference between the first and the second line.